Business Context and Reporting Period
Company: Capsovision, Inc. (CV)
Filing Type: Form 10-Q (Unaudited)
Period: Three months ended March 31, 2026
Business Overview: Capsovision is a medical technology company developing capsule endoscopy solutions for gastrointestinal (GI) imaging. Its primary commercial product is the CapsoCam Plus for small bowel imaging. The company is currently developing the CapsoCam Colon for large intestine imaging and exploring AI-enhanced pathology detection and new indications such as pancreatic cancer detection.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Net Revenue | $2,792 | $2,783 |
| Gross Profit | $1,329 | $1,494 |
| Gross Margin | 48% | 54% |
| Operating Loss | $(7,093) | $(5,382) |
| Net Loss | $(7,033) | $(5,375) |
| Net Loss Per Share (Basic & Diluted) | $(0.15) | $(2.49) |
| Cash and Cash Equivalents (End of Period) | $17,933 | $4,398 |
| Net Cash Used in Operating Activities | $(6,066) | $(4,986) |
| Net Cash Provided by Financing Activities | $13,952 | $34 |
Liquidity & Debt: As of March 31, 2026, the company held $17.9 million in cash and cash equivalents. Total liabilities were $5.7 million, consisting primarily of accounts payable, accrued expenses, and operating lease liabilities. There is no long-term debt reported.
Material Changes vs. Prior Period
- Revenue: Revenue remained flat ($2.8 million) compared to Q1 2025. A 3% decrease in unit sales was offset by a 1% increase in average selling price.
- Gross Margin Compression: Gross margin declined from 54% to 48%. Management attributed the $165,000 decrease in gross profit to increased customs and tariff expenses resulting from changes in U.S. trade policies.
- Operating Expenses: Total operating expenses increased 22% to $8.4 million.
- R&D Expenses: Increased 43% to $4.4 million, driven by $0.9 million in clinical trial costs and $0.4 million in non-recurring engineering services (specifically a development agreement with Canon Inc.).
- Selling & Marketing: Increased 7% to $2.1 million due to headcount expansion and higher insurance costs.
- G&A Expenses: Increased 5% to $1.9 million, reflecting costs of operating as a public company and increased stock-based compensation.
- Financing Activity: The company closed a Private Placement on March 16, 2026, raising approximately $14 million in gross proceeds. This significantly improved cash balances compared to the prior year period.
Guidance, Outlook, and Risks
Going Concern Warning
The filing explicitly states that the company's financial statements raise substantial doubt about its ability to continue as a going concern within one year of the report date. Despite the recent $14 million capital raise, management does not believe current cash balances are sufficient to fund operations for the next 12 months without additional financing.
Product Pipeline & Regulatory Outlook
- CapsoCam Colon (2nd Gen): The company is prioritizing the second-generation product over the first. A pivotal study is underway with over 600 patients enrolled (targeting 800). The company expects to submit a 510(k) application to the FDA in Q3 2026, with commercialization targeted for mid-2027.
- AI Integration: An updated CapsoCam Plus with AI-assisted pathology detection is expected to receive FDA clearance by mid-2026.
- Pancreatic Cancer: A study for early pancreatic cancer detection using the CapsoCam UGI system began in May 2026 following an initial FDA response that did not approve the Breakthrough Device Designation application.
Material Risks
- Capital Requirements: The company will likely need to raise additional capital before the end of 2026 to fund clinical studies and operations. Failure to do so could force a scaling back of plans.
- Supply Chain & Geopolitics: Manufacturing relies heavily on single-source suppliers in Taiwan and Japan. Geopolitical tensions and tariffs pose significant risks to supply continuity and cost structures.
- Internal Controls: The company identified two material weaknesses in internal control over financial reporting (IT general controls and segregation of duties) as of March 31, 2026, which have not yet been fully remediated.
Investor Verification Checklist
- Cash Runway: Verify the specific timeline for the next capital raise given the "substantial doubt" going concern disclosure.
- Tariff Impact: Assess the long-term impact of U.S. trade policy changes on gross margins, as this was a primary driver of margin compression in Q1 2026.
- Canon Agreement: Review the remaining $2.2 million purchase commitment and the status of the CMOS image sensor development with Canon Inc.
- Internal Control Remediation: Monitor progress on the remediation of material weaknesses in internal controls, specifically regarding the new ERP system implementation and segregation of duties.
- Regulatory Milestones: Track the enrollment progress of the CapsoCam Colon pivotal study and the anticipated Q3 2026 510(k) submission date.